Back to Gene
GJB3 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

GJB3 gene

The GJB3 gene encodes the connexin 31 protein, which is critical for skin cell maturation and appears to play a role in the hearing process.

Normal Function

The GJB3 gene provides instructions for making a protein called gap junction beta 3, commonly known as connexin 31. This protein forms gap junctions that regulate the flow of nutrients, ions, and signaling molecules between cells. Connexin 31 is found in the epidermis, where it supports cell growth and maturation, and in the inner ear, where it is involved in hearing.

Health Conditions Related to Genetic Changes

Erythrokeratodermia variabilis et progressiva

Mutations in the GJB3 gene have been identified in individuals with erythrokeratodermia variabilis et progressiva (EKVP), a skin disorder characterized by:

  • Hyperkeratosis: Abnormally thickened skin.
  • Erythematous areas: Temporarily reddened patches of skin.

Research suggests that these mutations lead to the production of abnormal connexin 31 proteins that may accumulate in the endoplasmic reticulum (ER), causing "ER stress" and premature cell death in the epidermis. Other mutations may result in non-functional channels or interfere with the formation of other types of gap junctions, further contributing to epidermal damage.

Other Names for This Gene

  • connexin 31
  • CX31
  • CXB3_HUMAN
  • DFNA2
  • gap junction protein, beta 3, 31kDa
  • PNHI

Frequently Asked Questions

EKVP, linked to GJB3 gene mutations, is characterized by two main skin features: hyperkeratosis, which means abnormally thickened skin, and erythematous areas, which are patches of skin that temporarily become red. These patches can vary in size, shape, and location, and may change over time or in response to triggers.
Management of EKVP primarily focuses on symptom relief and improving skin appearance. This often involves topical treatments like emollients to moisturize and soften thickened skin, and keratolytics (such as urea or salicylic acid) to reduce hyperkeratosis. Oral retinoids may be used in more severe cases, but treatment plans are individualized based on the patient's specific symptoms and response.
While the GJB3 gene is involved in hearing, mutations specifically linked to erythrokeratodermia variabilis et progressiva (EKVP) primarily manifest as skin issues. The provided context does not explicitly state that GJB3 mutations causing EKVP also lead to hearing loss. However, other specific GJB3 mutations not related to EKVP have been associated with nonsyndromic hearing loss, so it depends on the exact mutation.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA